Cancentus is a biopharmaceutical company developing novel cancer therapies that exploit oncogene-induced DNA replication stress to selectively eliminate malignant cells while sparing healthy tissue. By targeting pathways cancer cells depend on to manage replication stress, the company aims to improve the therapeutic index—the balance between efficacy and patient safety. This precision approach moves beyond traditional cytotoxic treatments toward therapies designed for greater tolerability and clinical confidence.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional cancer therapies often damage healthy tissues alongside malignant cells, creating a narrow therapeutic index that limits dosing and leads to significant side effects. This toxicity constrains treatment efficacy and reduces patient quality of life, underscoring the need for more selective approaches that spare normal cells.
Solution
Cancentus develops precision cancer therapeutics that exploit oncogene-induced DNA replication stress, a fundamental vulnerability unique to cancer cells. By targeting the specific pathways that malignant cells depend on to manage this stress, the company aims to trigger irreversible cancer cell death while preserving normal tissue function. This strategy moves beyond traditional cytotoxic methods toward highly selective inhibitors designed to maximize the therapeutic index—the balance between efficacy and tolerability. The approach is intended to give physicians confidence in prescribing therapies that patients can better tolerate, potentially improving treatment outcomes and quality of life.
Target Audience
Primary customers are oncology drug development partners, including pharmaceutical companies and clinical research organizations, as well as physicians and patients who would ultimately benefit from more tolerable and effective cancer therapies.
Features
- Targets oncogene-induced DNA replication stress, a cancer-specific vulnerability not present in normal cells
- Selective inhibition of pathways whose blockade causes irreversible cancer cell death while sparing healthy tissue
- Precision therapeutic design aimed at optimizing the therapeutic index for improved patient tolerability
- Mechanism-based approach that distinguishes malignant cells from normal cells via aberrant oncogene activation
- Strategy designed to support clinical confidence through a favorable efficacy-to-toxicity profile